Suppr超能文献

钙调蛋白拮抗剂对免疫小鼠淋巴细胞的影响。

Effects of calmodulin antagonists on immune mouse lymphocytes.

作者信息

Wolberg G, Zimmerman T P

出版信息

Mol Pharmacol. 1984 Sep;26(2):286-92.

PMID:6482875
Abstract

The nature of the Ca2+ requirement of lymphocyte-mediated cytolysis (LMC) has been explored pharmacologically with a number of putative calmodulin antagonists. N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7), N-(6-aminohexyl)-1-naphthalenesulfonamide (W-5), trifluoperazine, and chlorpromazine were found to inhibit LMC (IC50 values = 8.9, approximately 50, 7.4, and 9.4 microM, respectively) at concentrations which were not detectably toxic to either the effector or the target cell. Pimozide inhibited LMC by 50% at 15 microM but caused a substantial decrease in lymphocyte ATP content and viability at this concentration. 1-[Bis(p-chlorophenyl)methyl]-3-[2,4-dichloro-beta-(2,4-dichlorobenzy loxy) phenethyl]imidazolium chloride (R 24 571, calmidazolium), which has been reported to be the most potent antagonist of isolated calmodulin, caused a marked decrease in lymphocyte ATP content and viability at concentrations greater than 4 microM and inhibited LMC only slightly at similar concentrations. Trifluoperazine sulfoxide and chlorpromazine sulfoxide were not inhibitory to LMC at less than or equal to 20 microM. LMC was inhibited in a sustained manner when cytolytic lymphocytes, but not target cells, were pretreated separately with W-7 or chlorpromazine at 37 degrees and were then washed free of exogenous drug prior to the start of the LMC assay. The above cellular effects of the calmodulin antagonists were reduced in magnitude when the serum concentration in the culture medium was increased (from 5% to 20%). The inhibition of LMC by micromolar concentrations of W-7, trifluoperazine, and chlorpromazine, as well as the relative inactivities of W-5 versus W-7 and of the sulfoxide derivatives of trifluoperazine and chlorpromazine, are consistent with calmodulin's being a lymphocyte receptor whose occupancy by Ca2+ is required for the performance of this cytolytic function. However, this conclusion must be tempered by the finding that even W-7, trifluoperazine, and chlorpromazine can exert nonspecific effects on the energy metabolism and viability of the cytolytic lymphocytes at concentrations of drug severalfold higher than those required to inhibit LMC.

摘要

已使用多种假定的钙调蛋白拮抗剂通过药理学方法探究了淋巴细胞介导的细胞溶解作用(LMC)对钙离子的需求性质。发现N-(6-氨基己基)-5-氯-1-萘磺酰胺(W-7)、N-(6-氨基己基)-1-萘磺酰胺(W-5)、三氟拉嗪和氯丙嗪在对效应细胞或靶细胞均无明显毒性的浓度下可抑制LMC(IC50值分别为8.9、约50、7.4和9.4微摩尔)。匹莫齐特在15微摩尔时可使LMC抑制50%,但在此浓度下会导致淋巴细胞ATP含量和活力大幅下降。据报道,1-[双(对氯苯基)甲基]-3-[2,4-二氯-β-(2,4-二氯苄氧基)苯乙基]咪唑氯化物(R 24 571,卡咪唑)是分离的钙调蛋白最有效的拮抗剂,在浓度大于4微摩尔时会导致淋巴细胞ATP含量和活力显著下降,而在相似浓度下对LMC的抑制作用仅轻微。三氟拉嗪亚砜和氯丙嗪亚砜在浓度小于或等于20微摩尔时对LMC无抑制作用。当溶细胞淋巴细胞而非靶细胞在37℃下分别用W-7或氯丙嗪预处理,然后在LMC测定开始前洗去外源药物时,LMC受到持续抑制。当培养基中的血清浓度增加(从5%增至20%)时,钙调蛋白拮抗剂的上述细胞效应强度会降低。微摩尔浓度的W-7、三氟拉嗪和氯丙嗪对LMC的抑制作用,以及W-5与W-7相比以及三氟拉嗪和氯丙嗪的亚砜衍生物的相对无活性,与钙调蛋白作为淋巴细胞受体一致,其被钙离子占据是执行这种溶细胞功能所必需的。然而,这一结论必须因以下发现而有所缓和:即使是W-7、三氟拉嗪和氯丙嗪在浓度比抑制LMC所需浓度高几倍时,也会对溶细胞淋巴细胞的能量代谢和活力产生非特异性影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验